spironolactone and Central Serous Chorioretinopathy studies

Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.

Central Serous Chorioretinopathy: A visual impairment characterized by the accumulation of fluid under the retina through a defect in the retinal pigment epithelium.

Research Excerpts

Excerpt	Relevance	Reference
"To compare the effectiveness and safety of spironolactone versus lecithin-bound iodine in patients with central serous retinopathy (CSR)."	9.69	Efficacy and safety of iodized lecithin tablets versus spironolactone in alleviating central serous retinopathy among Chinese patients with uncontrolled diabetes. ( Gu, H; Pu, L; Yu, S, 2023)
"To evaluate the safety and effects of oral eplerenone in chronic central serous chorioretinopathy."	9.27	A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROL PILOT STUDY OF EPLERENONE FOR THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY (ECSELSIOR). ( Adam, MK; Chiang, A; Fineman, MS; Hsu, J; Kaiser, RS; Pitcher, JD; Rahimy, E; Samara, WA; Shahlaee, A; Spirn, MJ; Vander, JF, 2018)
"To evaluate the efficacy of oral spironolactone in patients with acute central serous chorioretinopathy (CSC)."	9.27	Spironolactone versus observation in the treatment of acute central serous chorioretinopathy. ( Fang, W; Ge, W; Li, J; Liu, Q; Shuai, Y; Sun, X; Yuan, S, 2018)
"In eyes with persistent SRF due to central serous chorioretinopathy, spironolactone significantly reduced both the SRF and the subfoveal choroidal thickness as compared with placebo."	9.20	SPIRONOLACTONE FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY: A RANDOMIZED CONTROLLED CROSSOVER STUDY. ( Batista, R; Behar-Cohen, F; Bergin, C; Beydoun, T; Bousquet, E; Brandely, ML; Chast, F; Couraud, B; Farman, N; Gaudric, A; Rothschild, PR; Zhao, M, 2015)
"To evaluate the therapeutic effects and safety of oral spironolactone (SPRL) in patients with central serous chorioretinopathy (CSC)."	8.12	Therapeutic Efficacy of Spironolactone for Central Serous Chorioretinopathy. ( Byeon, SH; Choi, EY; Han, JY; Kim, M; Kim, SS; Kim, YJ; Lee, CS; Lee, J; Lee, JH, 2022)
"To assess the morphological and functional outcome of oral eplerenone for treatment of patients with chronic central serous chorioretinopathy (CSC) in a real life experience."	8.02	Eplerenone for treatment of chronic central serous chorioretinopathy. ( Abdin, AD; Fraenkel, D; Langenbucher, A; Seitz, B; Suffo, S, 2021)
"OBJECTıVE: The goal of this study was to investigate the efficacy and safety of oral spironolactone in patients with central serous chorioretinopathy (CSC)."	8.02	Investigating the efficacy and safety of oral spironolactone in patients with central serous chorioretinopathy. ( Balsak, S; Dursun, B; Karahan, M; Yavuz, S, 2021)
" Taking in consideration this response, she was then diagnosed with a bullous variant of central serous chorioretinopathy and treated with 50 mg of spironolactone per day."	7.96	SPIRONOLACTONE AS A THERAPEUTIC ALTERNATIVE FOR THE BULLOUS VARIANT OF CENTRAL SEROUS CHORIORETINOPATHY. ( Contreras-Mérida, SP; Muñoz-Domínguez, E; Ramos-Yau, EC; Valencia-Londoño, LM, 2020)
"To compare long-term visual/anatomical outcomes and recurrence rate between oral spironolactone (SPRL) treatment and half-dose photodynamic therapy for nonresolving central serous chorioretinopathy."	7.96	COMPARISON OF VISUAL/ANATOMICAL OUTCOMES AND RECURRENCE RATE BETWEEN ORAL SPIRONOLACTONE AND PHOTODYNAMIC THERAPY FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY. ( Kim, DY; Kim, JY; Lee, EK; Lee, JY, 2020)
"To compare the short-term therapeutic efficacy of oral spironolactone treatment with that of half-dose photodynamic therapy (PDT) in patients with nonresolving central serous chorioretinopathy."	7.91	COMPARISON OF SHORT-TERM EFFICACY BETWEEN ORAL SPIRONOLACTONE TREATMENT AND PHOTODYNAMIC THERAPY FOR THE TREATMENT OF NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY. ( Kim, H; Lee, CS; Lee, JH; Lee, SC, 2019)
"PurposeTo correlate function and structural optical coherence tomography (OCT) to optical coherence tomography angiography (OCT-A) measures in patients affected by central serous chorioretinopathy (CSC) and to describe their changes after treatments (ie oral eplerenone, half-fluence photodynamic therapy (PDT))."	7.88	Multimodal retinal imaging in central serous chorioretinopathy treated with oral eplerenone or photodynamic therapy. ( Baldin, G; Bandello, F; Cicinelli, MV; Marchese, A; Montorio, D; Querques, G; Querques, L; Rabiolo, A; Sacconi, R; Zucchiatti, I, 2018)
"To evaluate the efficacy and safety of eplerenone for chronic nonresolving central serous chorioretinopathy (CSC)."	7.85	Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study. ( Cohen, S; Goldenberg, D; Goldstein, M; Guzner-Gur, H; Habot-Wilner, Z; Loewenstein, A; Martinez, MR; Nutman, A; Schwartz, R; Shulman, S, 2017)
"To evaluate the efficacy of eplerenone, a mineralocorticoid receptor antagonist, in the treatment of chronic central serous chorioretinopathy (CSCR)."	7.83	[Eplerenone treatment in chronic central serous chorioretinopathy]. ( Denis, D; Gascon, P; Ho Wang Yin, G; Hoffart, L; Matonti, F; Sampo, M; Soler, V, 2016)
"To evaluate the effect of eplerenone on patients with long-term recurring central serous chorioretinopathy (CSC)."	7.83	Eplerenone in patients with chronic recurring central serous chorioretinopathy. ( Findl, O; Hackl, C; Hirnschall, N; Leisser, C; Plasenzotti, P, 2016)
"To present a case of central serous chorioretinopathy (CSC) treatment with spironolactone in a challenge-rechallenge pattern."	7.81	Central serous chorioretinopathy treatment with spironolactone: a challenge-rechallenge case. ( Pulido, CM; Ryan, EH, 2015)
"To evaluate the effect of oral eplerenone on subretinal fluid, visual acuity, and choroidal thickness in patients with chronic central serous chorioretinopathy (CSCR)."	7.81	Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series. ( Elliott, KS; Fineman, MS; Fischer, DH; Hsu, J; Pitcher, JD; Regillo, CD; Salz, DA; Spirn, MJ; Vander, JF, 2015)
"Spironolactone treatment was associated with the improvement of chronic CSC."	6.84	The relation of the serum aldosterone level and central serous chorioretinopathy - a pilot study. ( Gong, Q; Liu, QH; Sun, XH; Yuan, ST, 2017)
"Retreatment criteria for recurrence were: gain in sub-retinal fluid (SRF) of more than 25 % plus/or increase of central retinal thickness (CRT) of more than 50 μm plus visual symptoms compared to last visit."	6.84	Long-term results and recurrence rates after spironolactone treatment in non-resolving central serous chorio-retinopathy (CSCR). ( Herold, TR; Priglinger, SG; Rist, K; Ulbig, MW; Wolf, A, 2017)
"To compare the effectiveness and safety of spironolactone versus lecithin-bound iodine in patients with central serous retinopathy (CSR)."	5.69	Efficacy and safety of iodized lecithin tablets versus spironolactone in alleviating central serous retinopathy among Chinese patients with uncontrolled diabetes. ( Gu, H; Pu, L; Yu, S, 2023)
"To evaluate the efficacy of oral spironolactone in patients with acute central serous chorioretinopathy (CSC)."	5.27	Spironolactone versus observation in the treatment of acute central serous chorioretinopathy. ( Fang, W; Ge, W; Li, J; Liu, Q; Shuai, Y; Sun, X; Yuan, S, 2018)
"To evaluate the safety and effects of oral eplerenone in chronic central serous chorioretinopathy."	5.27	A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROL PILOT STUDY OF EPLERENONE FOR THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY (ECSELSIOR). ( Adam, MK; Chiang, A; Fineman, MS; Hsu, J; Kaiser, RS; Pitcher, JD; Rahimy, E; Samara, WA; Shahlaee, A; Spirn, MJ; Vander, JF, 2018)
"Patients with chronic central serous chorioretinopathy can safely be treated with eplerenone as it can reverse choroidal vasodilation with an accompanying resolution of the SRF and improvement in visual acuity."	5.24	MINERALOCORTICOID RECEPTOR ANTAGONIST TREATMENT IN BILATERAL CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: A COMPARATIVE STUDY OF EXUDATIVE AND NONEXUDATIVE FELLOW EYES. ( Ecsedy, M; Gergely, R; Kovács, I; Nagy, ZZ; Papp, A; Récsán, Z; Resch, M; Schneider, M, 2017)
"To evaluate the effect of oral spironolactone and eplerenone, two specific antagonists of the mineralocorticoid receptor, in central serous chorioretinopathy (CSCR)."	5.24	Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy. ( Behar-Cohen, F; Carrai, P; Ciardella, A; Nucci, P; Pichi, F, 2017)
"In eyes with persistent SRF due to central serous chorioretinopathy, spironolactone significantly reduced both the SRF and the subfoveal choroidal thickness as compared with placebo."	5.20	SPIRONOLACTONE FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY: A RANDOMIZED CONTROLLED CROSSOVER STUDY. ( Batista, R; Behar-Cohen, F; Bergin, C; Beydoun, T; Bousquet, E; Brandely, ML; Chast, F; Couraud, B; Farman, N; Gaudric, A; Rothschild, PR; Zhao, M, 2015)
"A meta-analysis comparing mineralocorticoid receptor (MR) antagonists (eplerenone or spironolactone) versus observation or placebo in the treatment of central serous chorioretinopathy (CSCR) based on best-corrected visual acuity (BCVA) and subretinal fluid (SRF) level data from randomized controlled trials (RCTs)."	5.01	Mineralocorticoid Receptor Antagonists in Central Serous Chorioretinopathy: A Meta-Analysis of Randomized Controlled Trials. ( Arroyo, JG; Seto, BK; Sun, P; Tandias, RM; Wang, SK, 2019)
"To evaluate the therapeutic effects and safety of oral spironolactone (SPRL) in patients with central serous chorioretinopathy (CSC)."	4.12	Therapeutic Efficacy of Spironolactone for Central Serous Chorioretinopathy. ( Byeon, SH; Choi, EY; Han, JY; Kim, M; Kim, SS; Kim, YJ; Lee, CS; Lee, J; Lee, JH, 2022)
"To assess the morphological and functional outcome of oral eplerenone for treatment of patients with chronic central serous chorioretinopathy (CSC) in a real life experience."	4.02	Eplerenone for treatment of chronic central serous chorioretinopathy. ( Abdin, AD; Fraenkel, D; Langenbucher, A; Seitz, B; Suffo, S, 2021)
"OBJECTıVE: The goal of this study was to investigate the efficacy and safety of oral spironolactone in patients with central serous chorioretinopathy (CSC)."	4.02	Investigating the efficacy and safety of oral spironolactone in patients with central serous chorioretinopathy. ( Balsak, S; Dursun, B; Karahan, M; Yavuz, S, 2021)
"To compare long-term visual/anatomical outcomes and recurrence rate between oral spironolactone (SPRL) treatment and half-dose photodynamic therapy for nonresolving central serous chorioretinopathy."	3.96	COMPARISON OF VISUAL/ANATOMICAL OUTCOMES AND RECURRENCE RATE BETWEEN ORAL SPIRONOLACTONE AND PHOTODYNAMIC THERAPY FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY. ( Kim, DY; Kim, JY; Lee, EK; Lee, JY, 2020)
" Taking in consideration this response, she was then diagnosed with a bullous variant of central serous chorioretinopathy and treated with 50 mg of spironolactone per day."	3.96	SPIRONOLACTONE AS A THERAPEUTIC ALTERNATIVE FOR THE BULLOUS VARIANT OF CENTRAL SEROUS CHORIORETINOPATHY. ( Contreras-Mérida, SP; Muñoz-Domínguez, E; Ramos-Yau, EC; Valencia-Londoño, LM, 2020)
"To compare the short-term therapeutic efficacy of oral spironolactone treatment with that of half-dose photodynamic therapy (PDT) in patients with nonresolving central serous chorioretinopathy."	3.91	COMPARISON OF SHORT-TERM EFFICACY BETWEEN ORAL SPIRONOLACTONE TREATMENT AND PHOTODYNAMIC THERAPY FOR THE TREATMENT OF NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY. ( Kim, H; Lee, CS; Lee, JH; Lee, SC, 2019)
"PurposeTo correlate function and structural optical coherence tomography (OCT) to optical coherence tomography angiography (OCT-A) measures in patients affected by central serous chorioretinopathy (CSC) and to describe their changes after treatments (ie oral eplerenone, half-fluence photodynamic therapy (PDT))."	3.88	Multimodal retinal imaging in central serous chorioretinopathy treated with oral eplerenone or photodynamic therapy. ( Baldin, G; Bandello, F; Cicinelli, MV; Marchese, A; Montorio, D; Querques, G; Querques, L; Rabiolo, A; Sacconi, R; Zucchiatti, I, 2018)
"To evaluate the efficacy and safety of eplerenone for chronic nonresolving central serous chorioretinopathy (CSC)."	3.85	Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study. ( Cohen, S; Goldenberg, D; Goldstein, M; Guzner-Gur, H; Habot-Wilner, Z; Loewenstein, A; Martinez, MR; Nutman, A; Schwartz, R; Shulman, S, 2017)
"To evaluate the effect of eplerenone on patients with long-term recurring central serous chorioretinopathy (CSC)."	3.83	Eplerenone in patients with chronic recurring central serous chorioretinopathy. ( Findl, O; Hackl, C; Hirnschall, N; Leisser, C; Plasenzotti, P, 2016)
"To evaluate the efficacy of eplerenone, a mineralocorticoid receptor antagonist, in the treatment of chronic central serous chorioretinopathy (CSCR)."	3.83	[Eplerenone treatment in chronic central serous chorioretinopathy]. ( Denis, D; Gascon, P; Ho Wang Yin, G; Hoffart, L; Matonti, F; Sampo, M; Soler, V, 2016)
"To assess the effect of eplerenone on macular structure and function in patients with chronic central serous chorioretinopathy."	3.83	The use of mineralocorticoid receptor antagonists in chronic central serous chorioretinopathy. ( Filemonowicz-Skoczek, A; Karska-Basta, I; Kubicka-Trzaska, A; Ozog-Baran, J; Pociej-Marciak, W; Romanowska-Dixon, B, 2016)
"To present a case of central serous chorioretinopathy (CSC) treatment with spironolactone in a challenge-rechallenge pattern."	3.81	Central serous chorioretinopathy treatment with spironolactone: a challenge-rechallenge case. ( Pulido, CM; Ryan, EH, 2015)
"To evaluate the effect of oral eplerenone on subretinal fluid, visual acuity, and choroidal thickness in patients with chronic central serous chorioretinopathy (CSCR)."	3.81	Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series. ( Elliott, KS; Fineman, MS; Fischer, DH; Hsu, J; Pitcher, JD; Regillo, CD; Salz, DA; Spirn, MJ; Vander, JF, 2015)
"Retreatment criteria for recurrence were: gain in sub-retinal fluid (SRF) of more than 25 % plus/or increase of central retinal thickness (CRT) of more than 50 μm plus visual symptoms compared to last visit."	2.84	Long-term results and recurrence rates after spironolactone treatment in non-resolving central serous chorio-retinopathy (CSCR). ( Herold, TR; Priglinger, SG; Rist, K; Ulbig, MW; Wolf, A, 2017)
"Spironolactone treatment was associated with the improvement of chronic CSC."	2.84	The relation of the serum aldosterone level and central serous chorioretinopathy - a pilot study. ( Gong, Q; Liu, QH; Sun, XH; Yuan, ST, 2017)
"Eplerenone (EPL) is a selective mineralocorticoid receptor antagonist that is primarily used to treat hypertension."	2.82	Eplerenone repurposing in management of chorioretinopathy: Mechanism, nanomedicine-based delivery applications and future trends. ( Abdelhakeem, E; El-Nabarawi, M; Shamma, R, 2022)

Research

Studies (51)

Authors

Clinical Trials (4)

Trial Overview

Trial Outcomes

Change in Best Corrected Visual Acuity

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	36 (70.59)	24.3611
2020's	15 (29.41)	2.80

Authors	Studies
Abdelhakeem, E	1
El-Nabarawi, M	1
Shamma, R	1
Han, JY	1
Kim, YJ	1
Choi, EY	1
Lee, J	1
Lee, JH	2
Kim, M	1
Byeon, SH	1
Kim, SS	1
Lee, CS	2
Singh, SR	1
Goté, JT	1
Chhablani, J	1
Gu, H	1
Pu, L	1
Yu, S	2
Bousquet, E	5
Zhao, M	3
Daruich, A	2
Behar-Cohen, F	6
Fusi-Rubiano, W	1
Saedon, H	1
Patel, V	1
Yang, YC	1
Rabiolo, A	2
Bandello, F	2
Sadda, SR	1
Fraenkel, D	1
Suffo, S	1
Langenbucher, A	1
Seitz, B	1
Abdin, AD	1
Sacconi, R	2
Borrelli, E	1
Querques, G	3
Stanescu-Segall, D	1
Touhami, S	1
Bodaghi, B	1
LeHoang, P	1
Lotery, A	2
O'Connell, A	2
Harris, RA	1
Sivaprasad, S	2
Reeves, BC	1
Yavuz, S	1
Balsak, S	1
Karahan, M	1
Dursun, B	1
Reeves, B	1
Rahimy, E	1
Pitcher, JD	2
Hsu, J	2
Adam, MK	1
Shahlaee, A	1
Samara, WA	1
Vander, JF	2
Kaiser, RS	1
Chiang, A	1
Spirn, MJ	2
Fineman, MS	2
Schwartz, R	1
Habot-Wilner, Z	1
Martinez, MR	1
Nutman, A	1
Goldenberg, D	1
Cohen, S	1
Shulman, S	1
Guzner-Gur, H	1
Loewenstein, A	1
Goldstein, M	1
Ben Salem, S	1
Sithom, A	1
Ben Dhia, I	1
Khelifi, T	1
Askri, H	1
Ayed, A	1
Sun, X	1
Shuai, Y	1
Fang, W	1
Li, J	1
Ge, W	1
Yuan, S	1
Liu, Q	1
Lee, SC	1
Kim, H	1
Zucchiatti, I	1
Marchese, A	1
Baldin, G	1
Montorio, D	1
Cicinelli, MV	1
Querques, L	1
Ramos-Yau, EC	1
Muñoz-Domínguez, E	1
Contreras-Mérida, SP	1
Valencia-Londoño, LM	1
Suzuki, A	1
Takano, Y	1
Ando, Y	1
Ogawa, J	1
Ishida, M	1
Baba, A	1
Imamura, Y	1
Pociej-Marciak, W	1
Karska-Basta, I	1
Ozog-Baran, J	1
Kubicka-Trzaska, A	1
Filemonowicz-Skoczek, A	1
Romanowska-Dixon, B	1
Cakir, B	2
Agostini, H	2
Lange, C	2
Dhundass, M	1
Lejoyeux, R	1
Shinojima, A	1
Krivosic, V	1
Mrejen, S	2
Gaudric, A	2
Tadayoni, R	1
Zola, M	1
Matet, A	1
Mantel, I	1
Kim, DY	1
Lee, JY	1
Lee, EK	1
Kim, JY	1
Wang, SK	1
Sun, P	1
Tandias, RM	1
Seto, BK	1
Arroyo, JG	1
Awasthi, U	1
Grover, R	1
Varshney, A	1
Videkar, C	1
Nentwich, MM	1
Ulbig, M	1
Maier, M	1
Stumpfe, S	1
Feucht, N	1
Strobl, P	1
Rath, V	1
Lohmann, CP	1
Breukink, MB	1
den Hollander, AI	1
Keunen, JE	1
Boon, CJ	1
Hoyng, CB	1
Sizmaz, S	1
Esen, E	1
Barman, S	1
Demircan, N	1
Herold, TR	2
Prause, K	1
Wolf, A	2
Mayer, WJ	1
Ulbig, MW	2
Ryan, EH	1
Pulido, CM	1
Salz, DA	1
Regillo, CD	1
Elliott, KS	1
Fischer, DH	1
Kouassi, AC	1
Masse, H	1
Lebreton, O	1
Weber, M	1
Beydoun, T	1
Rothschild, PR	1
Bergin, C	1
Batista, R	1
Brandely, ML	1
Couraud, B	1
Farman, N	2
Chast, F	1
Ghadiali, Q	1
Jung, JJ	1
Patel, SN	1
Yannuzzi, LA	1
Yannuzzi, NA	1
Capuano, V	1
Bhavsar, KV	1
Freund, KB	1
Leisser, C	1
Hirnschall, N	1
Hackl, C	1
Plasenzotti, P	1
Findl, O	1
Kapoor, KG	1
Wagner, AL	1
Fischer, F	1
Ehlken, C	1
Bühler, A	1
Stahl, A	1
Schlunck, G	1
Böhringer, D	1
Sampo, M	1
Soler, V	1
Gascon, P	1
Ho Wang Yin, G	1
Hoffart, L	1
Denis, D	1
Matonti, F	1
Rist, K	1
Priglinger, SG	1
Gergely, R	1
Kovács, I	1
Schneider, M	1
Resch, M	1
Papp, A	1
Récsán, Z	1
Nagy, ZZ	1
Ecsedy, M	1
Pichi, F	1
Carrai, P	1
Ciardella, A	1
Nucci, P	1
Yang, D	1
Eliott, D	1
Gong, Q	1
Sun, XH	1
Yuan, ST	1
Liu, QH	1
Célérier, I	1
Jeanny, JC	1
Jonet, L	1
Savoldelli, M	1
Offret, O	1
Curan, A	1
Jaisser, F	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Non-Responsive Diabetic Macular Edema in Patients With Pachychoroid and Choroidal Hyperpermeability.[NCT04853355]	Phase 4	0 participants (Actual)	Interventional	2022-07-31	Withdrawn (stopped due to lack of funding)
[NCT02153125]	Phase 2	30 participants (Anticipated)	Interventional	2014-04-30	Recruiting
Short-Term Oral Mifepristone for Central Serous Chorioretinopathy. A Placebo-controlled Dose Ranging Study of Mifepristone in the Treatment of CSC (STOMP-CSC)[NCT02354170]	Phase 2	16 participants (Actual)	Interventional	2015-01-31	Completed
Eplerenone for Central Serous Chorioretinopathy: A Pilot Study[NCT01822561]	Phase 2	17 participants (Actual)	Interventional	2013-05-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Visual acuity will be measured with standard eye charts, with manifest refraction at the initiation and conclusion of treatment. Although an important measure, this was not chosen as the primary outcome measure, as some patients with central serous chorioretinopathy may have a normal visual acuity when properly refracted (refraction can change with elevation of the macula by sub-retinal fluid) (NCT01822561)
Timeframe: Baseline and 1 month after treatment

Change in Macular Thickness

Intervention	logMAR (Mean)
Patients That Took Eplerenone	-0.03

Automated software to calculate the thickness of the macula is standard on commercial OCT devices. Macular thickness before and after treatment will be assessed and compared. (NCT01822561)
Timeframe: Baseline and 1 month after treatment

Change in Serum Potassium

Intervention	Microns (Mean)
Patients That Received Eplerenone	-26

Eplerenone can cause elevation of serum potassium. After initial screening, serum potassium was evaluated at 1 and 4 weeks after baseline. (NCT01822561)
Timeframe: Baseline and 1 month after treatment

Change in Subfoveal Choroidal Thickness, Study Eye

Intervention	mEq/L (Mean)
Patients That Received Eplerenone	0.11

Choroidal thickness can be measured using optical coherence tomography, and is known to be affected in patients with central serous chorioretinopathy. Thickness of the choroid under the fovea will be manually calculated in both the study eye. (NCT01822561)
Timeframe: Baseline and 1 month after treatment

Complete Resolution of Subretinal Fluid

Intervention	microns (Mean)
Patients That Received Eplerenone	29.8

Optical coherence tomography is an imaging technique capable of extremely high resolution (~5-7 microns) imaging of the macula, and is able to detect the presence and amount of subretinal fluid present, the key anatomic abnormality in Central Serous Chorioretinopathy (NCT01822561)
Timeframe: Baseline and 1 month after treatment

Reviews

Trials

Other Studies

35 other studies available for spironolactone and Central Serous Chorioretinopathy

Article	Year
Eplerenone repurposing in management of chorioretinopathy: Mechanism, nanomedicine-based delivery applications and future trends. British journal of clinical pharmacology, 2022, Volume: 88, Issue:6 Topics: Central Serous Chorioretinopathy; Chronic Disease; Eplerenone; Humans; Mineralocorticoid Receptor An	2022
Randomized controlled trials in central serous chorioretinopathy: A review. Eye (London, England), 2023, Volume: 37, Issue:16 Topics: Central Serous Chorioretinopathy; Eplerenone; Humans; Randomized Controlled Trials as Topic; Spirono	2023
Mineralocorticoid antagonists in the treatment of central serous chorioetinopathy: Review of the pre-clinical and clinical evidence. Experimental eye research, 2019, Volume: 187 Topics: Central Serous Chorioretinopathy; Drug Evaluation, Preclinical; Eplerenone; Humans; Mineralocorticoi	2019
Oral medications for central serous chorioretinopathy: a literature review. Eye (London, England), 2020, Volume: 34, Issue:5 Topics: Central Serous Chorioretinopathy; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Photoc	2020
[Treatment of central serous chorioretinopathy with mineralocorticoid receptor antagonists]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2019, Volume: 116, Issue:2 Topics: Central Serous Chorioretinopathy; Fluorescein Angiography; Humans; Mineralocorticoid Receptor Antago	2019
Mineralocorticoid Receptor Antagonists in Central Serous Chorioretinopathy: A Meta-Analysis of Randomized Controlled Trials. Ophthalmology. Retina, 2019, Volume: 3, Issue:2 Topics: Central Serous Chorioretinopathy; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Random	2019
Systemic Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy. Seminars in ophthalmology, 2017, Volume: 32, Issue:1 Topics: Central Serous Chorioretinopathy; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Spiron	2017

Article	Year
Efficacy and safety of iodized lecithin tablets versus spironolactone in alleviating central serous retinopathy among Chinese patients with uncontrolled diabetes. Pakistan journal of pharmaceutical sciences, 2023, Volume: 36, Issue:2(Special) Topics: Central Serous Chorioretinopathy; Diabetes Mellitus; East Asian People; Halogenation; Humans; Iodize	2023
A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROL PILOT STUDY OF EPLERENONE FOR THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY (ECSELSIOR). Retina (Philadelphia, Pa.), 2018, Volume: 38, Issue:5 Topics: Administration, Oral; Adult; Aged; Central Serous Chorioretinopathy; Chronic Disease; Double-Blind M	2018
Spironolactone versus observation in the treatment of acute central serous chorioretinopathy. The British journal of ophthalmology, 2018, Volume: 102, Issue:8 Topics: Acute Disease; Administration, Oral; Adult; Central Serous Chorioretinopathy; Female; Fluorescein An	2018
Predictive Factors of Response to Mineralocorticoid Receptor Antagonists in Nonresolving Central Serous Chorioretinopathy. American journal of ophthalmology, 2019, Volume: 198 Topics: Administration, Oral; Adult; Aged; Central Serous Chorioretinopathy; Choroid; Eplerenone; Female; Fl	2019
SPIRONOLACTONE FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY: A RANDOMIZED CONTROLLED CROSSOVER STUDY. Retina (Philadelphia, Pa.), 2015, Volume: 35, Issue:12 Topics: Adult; Aged; Central Serous Chorioretinopathy; Cross-Over Studies; Double-Blind Method; Female; Huma	2015
Long-term results and recurrence rates after spironolactone treatment in non-resolving central serous chorio-retinopathy (CSCR). Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2017, Volume: 255, Issue:2 Topics: Central Serous Chorioretinopathy; Choroid; Female; Fluorescein Angiography; Follow-Up Studies; Fundu	2017
MINERALOCORTICOID RECEPTOR ANTAGONIST TREATMENT IN BILATERAL CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: A COMPARATIVE STUDY OF EXUDATIVE AND NONEXUDATIVE FELLOW EYES. Retina (Philadelphia, Pa.), 2017, Volume: 37, Issue:6 Topics: Administration, Oral; Adult; Aged; Central Serous Chorioretinopathy; Choroid; Chronic Disease; Epler	2017
Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy. International ophthalmology, 2017, Volume: 37, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Central Serous Chorioretinopathy; Dose-Response Relationship, Drug;	2017
The relation of the serum aldosterone level and central serous chorioretinopathy - a pilot study. European review for medical and pharmacological sciences, 2017, Volume: 21, Issue:3 Topics: Adult; Aldosterone; Central Serous Chorioretinopathy; Choroid; Female; Fluorescein Angiography; Huma	2017

Article	Year
Therapeutic Efficacy of Spironolactone for Central Serous Chorioretinopathy. Yonsei medical journal, 2022, Volume: 63, Issue:4 Topics: Adult; Aged; Central Serous Chorioretinopathy; Fluorescein Angiography; Humans; Male; Middle Aged; R	2022
Eplerenone is not superior to placebo for chronic central serous chorioretinopathy. Lancet (London, England), 2020, 01-25, Volume: 395, Issue:10220 Topics: Central Serous Chorioretinopathy; Double-Blind Method; Eplerenone; Humans; Mineralocorticoid Recepto	2020
Lack of efficacy of eplerenone for treatment of active central serous chorioretinopathy. Eye (London, England), 2020, Volume: 34, Issue:9 Topics: Central Serous Chorioretinopathy; Eplerenone; Fluorescein Angiography; Humans; Mineralocorticoid Rec	2020
Eplerenone for treatment of chronic central serous chorioretinopathy. European journal of ophthalmology, 2021, Volume: 31, Issue:4 Topics: Administration, Oral; Central Serous Chorioretinopathy; Chronic Disease; Eplerenone; Fluorescein Ang	2021
Eplerenone for chronic central serous chorioretinopathy. Lancet (London, England), 2020, 11-14, Volume: 396, Issue:10262 Topics: Central Serous Chorioretinopathy; Double-Blind Method; Eplerenone; Humans; Mineralocorticoid Recepto	2020
Eplerenone for chronic central serous chorioretinopathy. Lancet (London, England), 2020, 11-14, Volume: 396, Issue:10262 Topics: Central Serous Chorioretinopathy; Double-Blind Method; Eplerenone; Humans; Mineralocorticoid Recepto	2020
Eplerenone for chronic central serous chorioretinopathy - Authors' reply. Lancet (London, England), 2020, 11-14, Volume: 396, Issue:10262 Topics: Central Serous Chorioretinopathy; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Spiron	2020
Investigating the efficacy and safety of oral spironolactone in patients with central serous chorioretinopathy. Journal francais d'ophtalmologie, 2021, Volume: 44, Issue:1 Topics: Administration, Oral; Central Serous Chorioretinopathy; Fluorescein Angiography; Follow-Up Studies;	2021
Reply to: 'Current perspectives on the use of eplerenone for chronic central serous chorioretinopathy'. Eye (London, England), 2021, Volume: 35, Issue:12 Topics: Central Serous Chorioretinopathy; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Spiron	2021
Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study. Acta ophthalmologica, 2017, Volume: 95, Issue:7 Topics: Administration, Oral; Adolescent; Adult; Aged; Central Serous Chorioretinopathy; Choroid; Chronic Di	2017
Central serous chorioretinopathy after nasal corticosteroids in the aviator. La Tunisie medicale, 2016, Volume: 94, Issue:12 Topics: Adrenal Cortex Hormones; Adult; Central Serous Chorioretinopathy; Fluorescein Angiography; Humans; M	2016
COMPARISON OF SHORT-TERM EFFICACY BETWEEN ORAL SPIRONOLACTONE TREATMENT AND PHOTODYNAMIC THERAPY FOR THE TREATMENT OF NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY. Retina (Philadelphia, Pa.), 2019, Volume: 39, Issue:1 Topics: Administration, Oral; Central Serous Chorioretinopathy; Female; Fluorescein Angiography; Follow-Up S	2019
Multimodal retinal imaging in central serous chorioretinopathy treated with oral eplerenone or photodynamic therapy. Eye (London, England), 2018, Volume: 32, Issue:1 Topics: Administration, Oral; Adult; Central Serous Chorioretinopathy; Choroid; Eplerenone; Female; Fluoresc	2018
SPIRONOLACTONE AS A THERAPEUTIC ALTERNATIVE FOR THE BULLOUS VARIANT OF CENTRAL SEROUS CHORIORETINOPATHY. Retinal cases & brief reports, 2020,Fall, Volume: 14, Issue:4 Topics: Central Serous Chorioretinopathy; Female; Fluorescein Angiography; Humans; Middle Aged; Mineralocort	2020
Mineralocorticoid receptor inhibitor for long-standing central serous chorioretinopathy. Acta ophthalmologica, 2018, Volume: 96, Issue:5 Topics: Administration, Oral; Central Serous Chorioretinopathy; Dose-Response Relationship, Drug; Eplerenone	2018
The use of mineralocorticoid receptor antagonists in chronic central serous chorioretinopathy. Klinika oczna, 2016, Volume: 118, Issue:1 Topics: Adult; Aged; Central Serous Chorioretinopathy; Choroid; Chronic Disease; Eplerenone; Female; Humans;	2016
Two-year follow-up of mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy. The British journal of ophthalmology, 2019, Volume: 103, Issue:8 Topics: Administration, Oral; Adult; Aged; Central Serous Chorioretinopathy; Choroid; Chronic Disease; Femal	2019
COMPARISON OF VISUAL/ANATOMICAL OUTCOMES AND RECURRENCE RATE BETWEEN ORAL SPIRONOLACTONE AND PHOTODYNAMIC THERAPY FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY. Retina (Philadelphia, Pa.), 2020, Volume: 40, Issue:6 Topics: Administration, Oral; Central Serous Chorioretinopathy; Female; Fluorescein Angiography; Fundus Ocul	2020
Predictive Factors of Response to Mineralocorticoid Receptor Antagonists in Nonresolving Central Serous Chorioretinopathy. American journal of ophthalmology, 2019, Volume: 203 Topics: Central Serous Chorioretinopathy; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Su	2019
[Paracentral retinal changes]. Klinische Monatsblatter fur Augenheilkunde, 2013, Volume: 230, Issue:10 Topics: Central Serous Chorioretinopathy; Combined Modality Therapy; Diagnosis, Differential; Humans; Male;	2013
[Mineralocorticoid receptor antagonists as treatment option for acute and chronic central serous chorioretinopathy]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2014, Volume: 111, Issue:2 Topics: Acute Disease; Adult; Central Serous Chorioretinopathy; Chronic Disease; Dose-Response Relationship,	2014
The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy. Acta ophthalmologica, 2014, Volume: 92, Issue:6 Topics: Administration, Oral; Adult; Central Serous Chorioretinopathy; Chronic Disease; Eplerenone; Female;	2014
To the editor. Retina (Philadelphia, Pa.), 2014, Volume: 34, Issue:8 Topics: Central Serous Chorioretinopathy; Female; Humans; Male; Mineralocorticoid Receptor Antagonists; Spir	2014
Reply: To PMID 23719402. Retina (Philadelphia, Pa.), 2014, Volume: 34, Issue:8 Topics: Central Serous Chorioretinopathy; Female; Humans; Male; Mineralocorticoid Receptor Antagonists; Spir	2014
Spironolactone in the treatment of central serous chorioretinopathy - a case series. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2014, Volume: 252, Issue:12 Topics: Administration, Oral; Adult; Central Serous Chorioretinopathy; Female; Fluorescein Angiography; Huma	2014
Central serous chorioretinopathy treatment with spironolactone: a challenge-rechallenge case. Retinal cases & brief reports, 2015,Summer, Volume: 9, Issue:3 Topics: Adult; Central Serous Chorioretinopathy; Humans; Male; Mineralocorticoid Receptor Antagonists; Recur	2015
Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series. Ophthalmic surgery, lasers & imaging retina, 2015, Volume: 46, Issue:4 Topics: Administration, Oral; Adult; Aged; Central Serous Chorioretinopathy; Choroid; Chronic Disease; Epler	2015
[Treatment of diffuse retinal pigment epitheliopathies by antialdosterones or by photodynamic therapy]. Journal francais d'ophtalmologie, 2015, Volume: 38, Issue:6 Topics: Central Serous Chorioretinopathy; Eplerenone; Follow-Up Studies; Humans; Mineralocorticoid Receptor	2015
CENTRAL SEROUS CHORIORETINOPATHY TREATED WITH MINERALOCORTICOID ANTAGONISTS: A ONE-YEAR PILOT STUDY. Retina (Philadelphia, Pa.), 2016, Volume: 36, Issue:3 Topics: Adult; Aged; Central Serous Chorioretinopathy; Eplerenone; Female; Humans; Male; Middle Aged; Minera	2016
A Central Hyporeflective Subretinal Lucency Correlates With a Region of Focal Leakage on Fluorescein Angiography in Eyes With Central Serous Chorioretinopathy. Ophthalmic surgery, lasers & imaging retina, 2015, Volume: 46, Issue:8 Topics: Adult; Aged; Angiogenesis Inhibitors; Capillary Permeability; Central Serous Chorioretinopathy; Fema	2015
Eplerenone in patients with chronic recurring central serous chorioretinopathy. European journal of ophthalmology, 2016, Aug-04, Volume: 26, Issue:5 Topics: Aged; Central Serous Chorioretinopathy; Chronic Disease; Eplerenone; Female; Fluorescein Angiography	2016
Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy: A Comparative Analysis. Ophthalmic research, 2016, Volume: 56, Issue:1 Topics: Administration, Oral; Adult; Central Serous Chorioretinopathy; Dose-Response Relationship, Drug; Epl	2016
Clinical experience with eplerenone to treat chronic central serous chorioretinopathy. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2016, Volume: 254, Issue:11 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Central Serous Chorioretinopathy; Chronic Dise	2016
[Eplerenone treatment in chronic central serous chorioretinopathy]. Journal francais d'ophtalmologie, 2016, Volume: 39, Issue:6 Topics: Adult; Aged; Central Serous Chorioretinopathy; Chronic Disease; Eplerenone; Female; Humans; Male; Mi	2016
Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. The Journal of clinical investigation, 2012, Volume: 122, Issue:7 Topics: Adult; Aldosterone; Animals; Central Serous Chorioretinopathy; Choroid; Corticosterone; Eplerenone;	2012
Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. The Journal of clinical investigation, 2012, Volume: 122, Issue:7 Topics: Adult; Aldosterone; Animals; Central Serous Chorioretinopathy; Choroid; Corticosterone; Eplerenone;	2012
Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. The Journal of clinical investigation, 2012, Volume: 122, Issue:7 Topics: Adult; Aldosterone; Animals; Central Serous Chorioretinopathy; Choroid; Corticosterone; Eplerenone;	2012
Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. The Journal of clinical investigation, 2012, Volume: 122, Issue:7 Topics: Adult; Aldosterone; Animals; Central Serous Chorioretinopathy; Choroid; Corticosterone; Eplerenone;	2012
Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. The Journal of clinical investigation, 2012, Volume: 122, Issue:7 Topics: Adult; Aldosterone; Animals; Central Serous Chorioretinopathy; Choroid; Corticosterone; Eplerenone;	2012
Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. The Journal of clinical investigation, 2012, Volume: 122, Issue:7 Topics: Adult; Aldosterone; Animals; Central Serous Chorioretinopathy; Choroid; Corticosterone; Eplerenone;	2012
Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. The Journal of clinical investigation, 2012, Volume: 122, Issue:7 Topics: Adult; Aldosterone; Animals; Central Serous Chorioretinopathy; Choroid; Corticosterone; Eplerenone;	2012
Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. The Journal of clinical investigation, 2012, Volume: 122, Issue:7 Topics: Adult; Aldosterone; Animals; Central Serous Chorioretinopathy; Choroid; Corticosterone; Eplerenone;	2012
Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. The Journal of clinical investigation, 2012, Volume: 122, Issue:7 Topics: Adult; Aldosterone; Animals; Central Serous Chorioretinopathy; Choroid; Corticosterone; Eplerenone;	2012